EGFR and non-small cell lung carcinoma: Intracranial recurrences were seen in 38 of 389 patients (9.8%) with EGFR-positive NSCLC, with predominance of parenchymal disease over leptomeningeal (37 patients [9.5%] vs 4 patients [1.0%]).